Rigel Pharmaceuticals, Inc.
RIGL
$41.50
-$0.49-1.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 105.77% | 70.30% | 54.84% | 21.65% | 7.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 105.62% | 70.16% | 54.71% | 21.73% | 7.56% |
| Cost of Revenue | 68.03% | 44.25% | 15.35% | -20.62% | -46.19% |
| Gross Profit | 114.80% | 78.33% | 69.48% | 40.93% | 42.27% |
| SG&A Expenses | 4.93% | 5.51% | 6.92% | -0.61% | -3.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.24% | 17.82% | 12.89% | -2.28% | -12.73% |
| Operating Income | 1,259.76% | 379.25% | 212.57% | 143.08% | 76.57% |
| Income Before Tax | 796.57% | 292.53% | 173.20% | 115.89% | 62.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 787.33% | 287.75% | 169.69% | 115.89% | 62.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 787.33% | 287.75% | 169.69% | 115.89% | 62.32% |
| EBIT | 1,259.76% | 379.25% | 212.57% | 143.08% | 76.57% |
| EBITDA | 1,542.22% | 420.83% | 230.45% | 154.83% | 80.12% |
| EPS Basic | 775.29% | 285.20% | 168.47% | 115.55% | 62.69% |
| Normalized Basic EPS | 784.42% | 280.75% | 169.17% | 114.55% | 66.41% |
| EPS Diluted | 760.73% | 281.56% | 165.85% | 114.81% | 62.81% |
| Normalized Diluted EPS | 774.34% | 278.16% | 167.97% | 114.42% | 66.41% |
| Average Basic Shares Outstanding | 1.43% | 1.22% | 1.05% | 0.97% | 0.95% |
| Average Diluted Shares Outstanding | 2.88% | 2.28% | 1.59% | 1.05% | 0.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |